Biogen and Eisai Receive FDA Approval for LEQEMBI IQLIK™ Subcutaneous Injection as At-Home Maintenance Therapy for Early Alzheimer’s Disease
I'm PortAI, I can summarize articles.
Biogen and Eisai have received FDA approval for LEQEMBI® IQLIK™, a subcutaneous injection for at-home maintenance treatment of early Alzheimer’s disease. This allows patients who completed 18 months of intravenous treatment to switch to a weekly injection or continue with monthly IV infusions. The approval aims to enhance access and reduce treatment burden for eligible patients in the U.S.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments